Skip to main content
. 2014 Dec;20(12):2006–2014. doi: 10.3201/eid2012.140548

Table 2. First passage VPSPr inoculations to Tg(HuPrP) mice harboring different PrP 129 genotypes from those of the inocula*.

Inoculum Tg(HuPrP) No. with clinical signs/total Histology, immunohistochemistry
PrPSc Western blot
No. positive/total Dpi positive/total† No. positive/total Dpi positive/total
VPSPr-129VV 6th‡ (129M)×1§
0/5 0/5 0/643 ± 71 NA NA
VPSPr-129VV 4th 0/4 0/4 0/659 ± 55 NA NA
VPSPr-129VV 5th
0/5
0/5
0/757 ± 57

NA
NA
VPSPr-129MV 1st (129M)×2
0/9 0/9 0/745 ± 70 NA NA
VPSPr-129MV 2nd 0/6 0/6 0/582 ± 101 NA NA
VPSPr-129MV 3rd
0/4
0/4
0/694 ± 153

NA
NA
VPSPr-129MV 4st (129V)×8 0/6 0/6 0/586 ± 68 NA NA
VPSPr-129MV 3rd 0/7 0/7 0/681 ± 102 NA NA

Dpi, days postinoculation; M, methionine; V, valine; NA, not available; VPSPr, variably protease-sensitive prionopathy associated with homozygosity V or M at codon 129 of the PrP gene (VPSPr-129VV or VPSPr-129MM).
†Dpi of positive mice compared with dpi of all mice (including positive mice). Each value represents the mean ± SD.
‡Identifies the VPSPr case-patients providing the inoculum, i.e., inocula were obtained from 5 case-patients with VPSPr-129VV and 2 with VPSPr-129MM.
§Refers to the presence of V or M at PrP residue 129 and expression level indicated as × normal.